Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Turnstone Biologics Corp. ( (TSBX) ) has shared an update.
On January 30, 2025, Turnstone Biologics decided to halt all clinical studies for TIDAL-01, a program targeting solid tumors, due to the high financial requirements and current market conditions. The company is now exploring strategic alternatives, such as mergers or sales, to maximize shareholder value while implementing cost-reduction measures, including workforce downsizing.
More about Turnstone Biologics Corp.
Turnstone Biologics is a clinical-stage biotechnology company specializing in the development of tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Their approach focuses on selecting and expanding the most potent tumor-reactive T cells to improve upon previous TIL therapies.
YTD Price Performance: -19.55%
Average Trading Volume: 276,521
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $10.01M
See more data about TSBX stock on TipRanks’ Stock Analysis page.
